| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ... Nature medicine 18 (4), 521-528, 2012 | 674 | 2012 |
| Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor MR Janes, JJ Limon, L So, J Chen, RJ Lim, MA Chavez, C Vu, MB Lilly, ... Nature medicine 16 (2), 205-213, 2010 | 477 | 2010 |
| Chemotherapy in malignant pleural mesothelioma. A review. ST Ong, NJ Vogelzang Journal of Clinical Oncology 14 (3), 1007-1017, 1996 | 311 | 1996 |
| FHIT and FRA3B 3p14.2 Allele Loss Are Common in Lung Cancer and Preneoplastic Bronchial Lesions and Are Associated with Cancer-related FHIT cDNA … KM Fong, EJ Biesterveld, A Virmani, I Wistuba, Y Sekido, SA Bader, ... Cancer research 57 (11), 2256-2267, 1997 | 270 | 1997 |
| Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin C Ly, AF Arechiga, JV Melo, CM Walsh, ST Ong Cancer research 63 (18), 5716-5722, 2003 | 226 | 2003 |
| Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function S Lim, TY Saw, M Zhang, MR Janes, K Nacro, J Hill, AQ Lim, CT Chang, ... Proceedings of the National Academy of Sciences 110 (25), E2298-E2307, 2013 | 159 | 2013 |
| Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia S Branford, DDH Kim, JF Apperley, CA Eide, S Mustjoki, ST Ong, ... Leukemia 33 (8), 1835-1850, 2019 | 129 | 2019 |
| Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition KP Ng, A Manjeri, KL Lee, W Huang, SY Tan, CTH Chuah, L Poellinger, ... Blood, The Journal of the American Society of Hematology 123 (21), 3316-3326, 2014 | 102 | 2014 |
| Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice ST Ong, ML Hackbarth, LC Degenstein, DA Baunoch, J Anastasi, ... Oncogene 16 (18), 2333-2343, 1998 | 98 | 1998 |
| Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer A Tanimoto, S Takeuchi, S Arai, K Fukuda, T Yamada, X Roca, ST Ong, ... Clinical Cancer Research 23 (12), 3139-3149, 2017 | 90 | 2017 |
| Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. ST Ong, MM Le Beau Seminars in oncology 25 (4), 447-460, 1998 | 78 | 1998 |
| Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance M Zhang, W Fu, S Prabhu, JC Moore, J Ko, JW Kim, BJ Druker, V Trapp, ... Molecular and cellular biology, 2008 | 77 | 2008 |
| The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors TK Ko, CTH Chuah, JWJ Huang, KP Ng, ST Ong Oncotarget 5 (19), 9033, 2014 | 70 | 2014 |
| A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation S Prabhu, D Saadat, M Zhang, L Halbur, JP Fruehauf, ST Ong Oncogene 26 (8), 1188-1200, 2007 | 68 | 2007 |
| Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14. 2 FV Rassool, MM Le Beau, ML Shen, ME Neilly, R Espinosa III, ST Ong, ... Genomics 35 (1), 109-117, 1996 | 61 | 1996 |
| An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia TK Ko, A Javed, KL Lee, TN Pathiraja, X Liu, S Malik, SX Soh, XT Heng, ... Blood, The Journal of the American Society of Hematology 135 (26), 2337-2353, 2020 | 59 | 2020 |
| Identification of cis-acting elements and splicing factors involved in the regulation of BIM Pre-mRNA splicing WC Juan, X Roca, ST Ong PloS one 9 (4), e95210, 2014 | 39 | 2014 |
| Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer S Takeuchi, T Hase, S Shimizu, M Ando, A Hata, H Murakami, ... Cancer science 111 (2), 561-570, 2020 | 38 | 2020 |
| A Fas-associated death domain protein/caspase-8-signaling axis promotes S-phase entry and maintains S6 kinase activity in T cells responding to IL-2 AF Arechiga, BD Bell, S Leverrier, BM Weist, M Porter, Z Wu, Y Kanno, ... The Journal of Immunology 179 (8), 5291-5300, 2007 | 38 | 2007 |
| Precise localization of the FHIT gene to the common fragile site at 3p14. 2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in … ST Ong, KM Fong, SA Bader, JD Minna, MM Le Beau, TW McKeithan, ... Genes, Chromosomes and Cancer 20 (1), 16-23, 1997 | 37 | 1997 |
